Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

Peripheral-immune-checkpoint blockade (P-ICB) with mAbs to PD-1 (nivolumab and pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) alone or combination with chemotherapy represents a novel active treatment for mNSCLC patients. However, this therapy can be associated to immune-related advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardone, Valerio, Giannicola, Rocco, Bianco, Giovanna, Giannarelli, Diana, Tini, Paolo, Pastina, Pierpaolo, Falzea, Antonia Consuelo, Macheda, Sebastiano, Caraglia, Michele, Luce, Amalia, Zappavigna, Silvia, Mutti, Luciano, Pirtoli, Luigi, Giordano, Antonio, Correale, Pierpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236817/
https://www.ncbi.nlm.nih.gov/pubmed/34195086
http://dx.doi.org/10.3389/fonc.2021.684110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236817/
https://www.ncbi.nlm.nih.gov/pubmed/34195086
http://dx.doi.org/10.3389/fonc.2021.684110

Ejemplares similares